Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study-Reference-Cited by-同舟云学术

Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study

Published:2018-10-19 Issue:6 Volume:54 Page:894-902
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Zhang Wei-Ping,Wang Zi-Wei,Hu Xiao-Xia,Chen Jie,Yang Dan,Song Xian-Min,Gao Lei,Ni Xiong,Chen Li,Xia Xin-Xin,Zhou Hong,Tang Gu-Sheng,Cheng Hui,Luo Yan-Rong,Li Hong-Mei,Yang Jian-Min,Wang Jian-Min

Funder

National Natural Science Foundation of China

Science and Technology Commission of Shanghai Municipality

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-018-0356-5.pdf

Reference44 articles.

1. Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, et al. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015;33:4167–75.

2. Tanaka Y, Kurosawa S, Tajima K, Tanaka T, Ito R, Inoue Y, et al. Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:553–9.